JNJ

230.16

+0.93%↑

UNH

371.5

+0.84%↑

TMO

476.61

+2.17%↑

ISRG

455.46

+0.87%↑

ABT

90.47

-1.62%↓

JNJ

230.16

+0.93%↑

UNH

371.5

+0.84%↑

TMO

476.61

+2.17%↑

ISRG

455.46

+0.87%↑

ABT

90.47

-1.62%↓

JNJ

230.16

+0.93%↑

UNH

371.5

+0.84%↑

TMO

476.61

+2.17%↑

ISRG

455.46

+0.87%↑

ABT

90.47

-1.62%↓

JNJ

230.16

+0.93%↑

UNH

371.5

+0.84%↑

TMO

476.61

+2.17%↑

ISRG

455.46

+0.87%↑

ABT

90.47

-1.62%↓

JNJ

230.16

+0.93%↑

UNH

371.5

+0.84%↑

TMO

476.61

+2.17%↑

ISRG

455.46

+0.87%↑

ABT

90.47

-1.62%↓

Search

Microbot Medical Inc

Aperta

2.08 1.96

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

2.03

Massimo

2.09

Metriche Chiave

By Trading Economics

Entrata

113K

-3.5M

Dipendenti

43

EBITDA

-561K

-4.1M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+257.14% upside

Dividendi

By Dow Jones

Utili prossimi

12 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-24M

146M

Apertura precedente

0.12

Chiusura precedente

2.08

Punteggio Tecnico

By Trading Central

Fiducia

Neutral Evidence

Microbot Medical Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 apr 2026, 23:53 UTC

Utili

Naver Posts Weaker First-Quarter Earnings

29 apr 2026, 23:41 UTC

Azioni calde

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 apr 2026, 23:55 UTC

Utili

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 apr 2026, 23:54 UTC

Utili

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 apr 2026, 23:52 UTC

Utili

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 apr 2026, 23:51 UTC

Utili

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 apr 2026, 23:51 UTC

Discorsi di Mercato

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 apr 2026, 23:34 UTC

Discorsi di Mercato

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 apr 2026, 23:24 UTC

Utili

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 apr 2026, 23:24 UTC

Utili

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 apr 2026, 23:24 UTC

Utili

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 apr 2026, 23:24 UTC

Utili

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 apr 2026, 23:22 UTC

Utili

China Longyuan 1Q Net CNY1.70B, Down 14%

29 apr 2026, 23:22 UTC

Utili

China Longyuan: Power Generation Down 2.9% as of End-March

29 apr 2026, 23:20 UTC

Utili

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 apr 2026, 23:20 UTC

Utili

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 apr 2026, 23:19 UTC

Utili

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 apr 2026, 23:19 UTC

Utili

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 apr 2026, 23:19 UTC

Utili

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 apr 2026, 23:19 UTC

Utili

China Vanke 1Q Loss Narrows>000002.SZ

29 apr 2026, 23:18 UTC

Utili

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 apr 2026, 23:17 UTC

Utili

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 apr 2026, 23:15 UTC

Utili

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 apr 2026, 23:15 UTC

Utili

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 apr 2026, 23:13 UTC

Utili

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 apr 2026, 23:12 UTC

Utili

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 apr 2026, 23:11 UTC

Utili

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 apr 2026, 23:11 UTC

Utili

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 apr 2026, 23:04 UTC

Utili

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 apr 2026, 23:04 UTC

Utili

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Confronto tra pari

Modifica del prezzo

Microbot Medical Inc Previsione

Obiettivo di Prezzo

By TipRanks

257.14% in crescita

Previsioni per 12 mesi

Media 7.5 USD  257.14%

Alto 12 USD

Basso 5 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Microbot Medical Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

3

Acquista

0

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

2.52 / 2.57Supporto e resistenza

A breve termine

Neutral Evidence

A termine intermedio

Very Strong Bullish Evidence

A lungo termine

Weak Bullish Evidence

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Microbot Medical Inc

Microbot Medical Inc., a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces. It also provides NovaCross, an intellectual property and technology in the field of intraluminal revascularization devices with anchoring mechanism and integrated microcatheter. The company has a strategic collaboration agreement with Stryker Corporation for technology co-development; and Phase 2 collaboration agreement with Corewell Health for the development of LIBERTY endovascular robotic system. Microbot Medical Inc. was founded in 2010 and is based in Braintree, Massachusetts.
help-icon Live chat